Literature DB >> 25210087

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M Dreyling1, C Geisler2, O Hermine3, H C Kluin-Nelemans4, S Le Gouill5, S Rule6, O Shpilberg7, J Walewski8, M Ladetto9.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25210087     DOI： 10.1093/annonc/mdu264

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  38 in total

1.  Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

Authors:  Martin Dreyling; Simone Ferrero
Journal:  Haematologica       Date:  2015-06       Impact factor: 9.941

2.  Haematological cancer: Bortezomib in MCL--new standard of care or just another option?

Authors:  Martin Dreyling
Journal:  Nat Rev Clin Oncol       Date:  2015-05-26       Impact factor: 66.675

3.  Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?

Authors:  Simone Ferrero; Martin Dreyling
Journal:  Haematologica       Date:  2017-07       Impact factor: 9.941

Review 4.  Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.

Authors:  Marco Ruella; Pierre Soubeyran
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

Authors:  Christian Winther Eskelund; Alexandra Albertsson-Lindblad; Arne Kolstad; Anna Laurell; Riikka Räty; Lone Bredo Pedersen; Christian Hartmann Geisler; Mats Jerkeman; Kirsten Grønbæk
Journal:  Haematologica       Date:  2018-05-24       Impact factor: 9.941

Review 6.  Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma?

Authors:  Satish Shanbhag; Nina Wagner-Johnston; Richard F Ambinder; Richard J Jones
Journal:  Curr Oncol Rep       Date:  2019-06-10       Impact factor: 5.075

7.  Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.

Authors:  Simon Rule; Martin Dreyling; Andre Goy; Georg Hess; Rebecca Auer; Brad Kahl; Nora Cavazos; Black Liu; Shiyi Yang; Fong Clow; Jenna D Goldberg; Darrin Beaupre; Jessica Vermeulen; Mark Wildgust; Michael Wang
Journal:  Br J Haematol       Date:  2017-08-18       Impact factor: 6.998

Review 8.  Optimizing therapy for mantle cell lymphoma.

Authors:  Peter Martin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

9.  Modulation of immune checkpoint molecule expression in mantle cell lymphoma.

Authors:  Bonnie K Harrington; Esther Wheeler; Kasey Hornbuckle; Arwa Y Shana'ah; Youssef Youssef; Lisa Smith; Quais Hassan; Brett Klamer; Xiaoli Zhang; Meixiao Long; Robert A Baiocchi; Kami Maddocks; Amy J Johnson; John C Byrd; Lapo Alinari
Journal:  Leuk Lymphoma       Date:  2019-03-01

10.  The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.

Authors:  Harald Holte; Klaus Beiske; Merrill Boyle; Gunhild Trøen; Yngvild N Blaker; June Myklebust; Sunniva Kvaløy; Andreas Rosenwald; Ole C Lingjaerde; Lisa M Rimsza; Erlend B Smeland; David W Scott; Arne Kolstad
Journal:  Br J Haematol       Date:  2018-08-06       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.